Document Detail

Effect of lower-molecular weight heparin in the prevention of pancreatic encephalopathy in the patient with severe acute pancreatitis.
MedLine Citation:
PMID:  20104197     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To study the effect of lower-molecular weight heparin in the prevention of pancreatic encephalopathy (PE) in the patient with severe acute pancreatitis (SAP). METHODS: Two hundred sixty-five SAP patients were randomly divided into 2 groups: (1) conventional treatment group (C group, n = 130) and (2) conventional treatment plus lower-molecular weight heparin treatment group (LT group, n = 135). The clinical parameters, laboratory parameters and computed tomographic (CT) score of pancreatic necrosis (CTSPN), incidence of PE, and mortality in the 2 groups were compared. RESULTS: On admission, all the clinical parameters, laboratory parameters, and CTSPN in the 2 groups were not significantly different (P > 0.05). However, 1 to 2 weeks after treatment, the symptoms and signs improvement rate, the levels of blood and urine amylase, the CT score, and the Acute Physiology and Chronic Health Evaluation II score in the LT group were obviously lower than those in the C group (P < 0.05-0.01), and PE occurrence rate, mortality, and mean hospital stay in LT group were obviously lower than those in the C group (P < 0.05-0.01). CONCLUSIONS: Lower-molecular weight heparin can enhance the effect of conventional treatment of SAP and can markedly decrease the PE incidence and improve the survival rate of SAP. Lower-molecular weight heparin is a simple, safe, less expensive, and effective method for treatment of SAP. It can be used in every hospital.
Xin-sheng Lu; Fu Qiu; Yi-xiong Li; Jie-qin Li; Qin-qiao Fan; Ri-guang Zhou
Related Documents :
24402557 - Predictive factors for failure after total knee replacement revision.
24674317 - Intensity modulated radiation therapy after radical prostatectomy: early results show n...
10361177 - Prospective randomized comparison between pylorus-preserving and standard pancreaticodu...
23451447 - Perception of leg length discrepancy after total hip replacement and its impact on qual...
17482847 - Biphosphonate-associated osteonecrosis can be controlled by nonsurgical management.
24141027 - Functional results after tme: j-pouch vs straight coloanal anastomosis and role of neoa...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Pancreas     Volume:  39     ISSN:  1536-4828     ISO Abbreviation:  Pancreas     Publication Date:  2010 May 
Date Detail:
Created Date:  2010-04-26     Completed Date:  2010-08-10     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8608542     Medline TA:  Pancreas     Country:  United States    
Other Details:
Languages:  eng     Pagination:  516-9     Citation Subset:  IM    
Department of General Surgery, Xiangya Hospital, Central South University, Changsha, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amylases / blood,  urine
Anticoagulants / therapeutic use
Brain Diseases / etiology,  prevention & control*
Fibrinogen / metabolism
Heparin, Low-Molecular-Weight / therapeutic use*
Length of Stay
Middle Aged
Pancreatitis, Acute Necrotizing / complications*
Partial Thromboplastin Time
Prothrombin Time
Treatment Outcome
Young Adult
Reg. No./Substance:
0/Anticoagulants; 0/Heparin, Low-Molecular-Weight; 9001-32-5/Fibrinogen; EC 3.2.1.-/Amylases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A New Neurogenic Vestibular Evoked Potential (N6) Recorded With the Use of Air-Conducted Sound.
Next Document:  Hospitalizations for Kawasaki Syndrome Among Children in the United States, 1997-2007.